ArticleFrontiers in psychiatry2025
Cognitive impairment across the schizophrenia spectrum: a comparative neuropsychological study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychosocial Interventions, Recovery, and Mediating Mechanisms in Schizophrenia-Spectrum Disorders: A Systematic Review and Meta-Analysis of Longitudinal Studies.Brain sciences · 2026Review
- Exploring Group Differences in Attenuated Symptoms and Functioning Between Clinical High-Risk Individuals With and Without Posttraumatic Stress Disorder.Early intervention in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cognitive impairment represents a core feature of schizophrenia spectrum disorders, predating psychosis onset and persisting throughout illness progression. This cross-sectional study systematically evaluates neurocognitive functioning across five critical populations: multi-episode chronic schizophrenia (MECS), first-episode psychosis (FEP), clinical high-risk (CHR) individuals, first-degree relatives (FDR), and healthy controls (HC). Methods: A comprehensive neuropsychological battery was administered to 366 participants: 40 MECS, 94 FEP, 54 CHR, 80 FDR, and 98 HC. Assessments included: Processing speed: Trail Making Test-A (TMT-A), Digit Symbol Coding Test (DST). Attention: Continuous Performance Test (CPT). Verbal memory: Hopkins Verbal Learning Test-Revised (HVLT-R).Visual memory: Brief Visuospatial Memory Test-Revised (BVMT-R). Executive function: Stroop Color and Word Test (SCWT). Group differences were analyzed using Analysis of Covariance (covariates: age, education) with Bonferroni correction, supplemented by multinomial logistic regression. Results: A stepwise gradient of impairment emerged across the schizophrenia spectrum (HC > FDR > CHR > FEP > MECS), with significant between-group differences ( Discussion: These findings support a stratified continuum of cognitive impairment across schizophrenia progression. While chronic patients manifest generalized deficits, at-risk populations demonstrate distinct profiles: FDR display subclinical vulnerabilities, whereas CHR show intermediate impairment exceeding familial risk but preceding acute psychosis. The differential trajectory of verbal memory and executive function deficits from FEP to MECS suggests progressive deterioration in higher-order cognitive domains. These gradient patterns may inform stage-specific cognitive interventions across the schizophrenia spectrum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.